Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RVRevolution Medicines, Inc. logo

Revolution Medicines, Inc. (RVMD)

NASDAQ Global Select · Currency in USD
$186.99 ▼ -0.70 (-0.37%)
At close: Oct 23, 4:00 PM ET. Market closed.
$189.00 ▲ +2.01 (+1.07%)
After hours: Oct 23, 7:54 PM ET

Summary

Previous Close
$187.69
Open
$187.59
Day's Range
$183.61 – $189.52
52 Week Range
$55.40 – $224.31
Volume
1,720,154
Avg. Volume
2,241,012
Market Cap
$40.08B
Beta (5Y Monthly)
1.40
PE Ratio (TTM)
--
EPS (TTM)
-$8.38
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$253.47

Profile: Revolution Medicines, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
883
CEO
Mark A. Goldsmith
Website
revmed.com

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$2.35 · Revenue est. $25.58M
DateEst.Actual
Aug 5, 2026-$2.04-$3.06Miss
May 6, 2026-$1.84-$2.29Miss
Feb 25, 2026-$1.58-$1.86Miss
Nov 5, 2025-$1.42-$1.61Miss
Aug 6, 2025-$1.14-$1.31Miss
May 7, 2025-$1.12-$1.13Miss

Analyst view

Consensus price target
$253.47 ▲ +35.6%
Range $179.00 – $320.00
Rating: Buy
Buy 92% · Hold 8% · Sell 0%

Get free alerts on RVMD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.